Haemodynamic effects of R 80122 immediately after cardiopulmonary bypass; preliminary results.
R 80122 is a new short-acting phosphodiesterase type III inhibitor. In a preliminary investigation, three patients, scheduled for coronary artery bypass surgery, were given R 80122 after weaning from cardiopulmonary bypass. Two patients received 10 micrograms.kg-1.min-1 for 10 min as a loading infusion followed by a 5 micrograms.kg-1.min-1 maintenance dose. One patient received a 20 micrograms.kg-1.min-1 for 10 min loading infusion followed by a 10 micrograms.kg-1.min-1 maintenance infusion. After weaning from cardiopulmonary bypass and during the administration period, no arrhythmias or cardiac ischaemia were detected. The administration of R 80122 improved the haemodynamic profile with an increase in cardiac output, a decrease in systemic vascular resistance and a stable heart rate and mean arterial blood pressure. These preliminary results indicate that R 80122 possesses positive inotropic activity in combination with vasodilating properties.
Herregods
L
L
Section of Cardiac Anaesthesia, University Hospital, Gent, Belgium.
Rolly
G
G
Van Belleghem
Y
Y
Van Nooten
G
G
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002315:Cardiopulmonary Bypass; D002316:Cardiotonic Agents / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects
D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D011799:Quinazolines; C076518:R 80122